UBS Group’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-4,743
Closed -$21.2K 10720
2024
Q3
$21.2K Buy
4,743
+4,116
+656% +$27.4K ﹤0.01% 7336
2024
Q2
$3.76K Buy
+627
New +$3.29K ﹤0.01% 8175
2024
Q1
Sell
-110
Closed -$551 10217
2023
Q4
$551 Buy
110
+103
+1,471% +$660 ﹤0.01% 8597
2023
Q3
$42 Sell
7
-43
-86% -$385 ﹤0.01% 9036
2023
Q2
$694 Buy
50
+34
+213% +$403 ﹤0.01% 8130
2023
Q1
$190 Sell
16
-570
-97% -$10.7K ﹤0.01% 9147
2022
Q4
$11.4K Buy
586
+292
+99% +$4.97K ﹤0.01% 8401
2022
Q3
$4K Sell
294
-36
-11% -$677 ﹤0.01% 9425
2022
Q2
$8K Buy
+330
New +$9.19K ﹤0.01% 8377
2022
Q1
Sell
-921
Closed -$27K 11082
2021
Q4
$27K Buy
+921
New +$36K ﹤0.01% 7513
2021
Q3
Sell
-83
Closed -$4.17K 10235
2021
Q2
$4K Sell
83
-416
-83% -$20.9K ﹤0.01% 8714
2021
Q1
$29K Buy
499
+100
+25% +$6.51K ﹤0.01% 7046
2020
Q4
$18K Buy
399
+254
+175% +$12.2K ﹤0.01% 7027
2020
Q3
$7K Sell
145
-452
-76% -$24.5K ﹤0.01% 7153
2020
Q2
$36K Buy
597
+531
+805% +$32.1K ﹤0.01% 6145
2020
Q1
$2K Sell
66
-29
-31% -$1.27K ﹤0.01% 7662
2019
Q4
$4K Sell
95
-234
-71% -$7.8K ﹤0.01% 7689
2019
Q3
$14K Buy
329
+68
+26% +$3.04K ﹤0.01% 6964
2019
Q2
$11K Buy
261
+155
+146% +$6.99K ﹤0.01% 7036
2019
Q1
$6K Sell
106
-20
-16% -$998 ﹤0.01% 7109
2018
Q4
$6K Sell
126
-516
-80% -$29.6K ﹤0.01% 7499
2018
Q3
$35K Buy
642
+636
+10,600% +$43K ﹤0.01% 6436
2018
Q2
$0 Sell
6
-43
-88% -$3.99K ﹤0.01% 8324
2018
Q1
$6K Buy
+49
New +$5.8K ﹤0.01% 7172

UBS Group's ORGS Position: Q4 2024 in Review

UBS Group sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2024, closing a stake of 4,743 shares — an estimated $21.2K sold.

UBS Group first reported a position in ORGS in Q1 2018 and held it in 24 quarters. The position peaked at $36K in Q2 2020. 0 funds tracked by Wall St. Rank hold ORGS as of Q4 2024.

  • UBS Group reported no remaining Orgenesis Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 4,743 Orgenesis Inc. Common Stock shares in Q4 2024, an estimated $21.2K.
  • UBS Group first reported a position in Orgenesis Inc. Common Stock in Q1 2018 and held it in 24 quarters.
  • UBS Group's Orgenesis Inc. Common Stock position peaked at $36K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.